MONT-SAINT-GUIBERT, Belgium, August 31 /PRNewswire/ --
- Symposium Session Draws Leading Experts to Review Recent Developments in Cardiac Regenerative Therapies
Cardio3 BioSciences, today provided an update and review of the clinical development of its unique C-Cure(R) therapy at the European Society of Cardiology Congress in Barcelona. A unique second generation stem-cell derived therapy, C-Cure allows the differentiation of a patient’s own cells into ‘cardiopoietic’ cells which grow into new heart cells and repair heart muscle. C-Cure is currently undergoing a randomized, multi-center pivotal trial, designed to evaluate the safety and efficacy beyond optimal clinical care in patients with heart failure, one of the world’s largest unmet medical needs.
The update was part of a broader satellite symposium at the Congress led by a panel of expert speakers. In addition to reviewing C-Cure the distinguished panel traced the progress made in the development of regenerative therapies for heart failure from first generation to second generation products.
The session was led by Prof. Stephanie Dimmeler (Institute for Cardiovascular Regeneration, Goethe University Frankfurt) and Prof. Michael Tendera (Head, Cardiology Division, Medical University of Silesia, Katowice, Poland) and included cardiology experts from leading European and U.S institutions: Dr Josef Bartunek (Cardiovascular Center Aalst, Belgium), Professors Dominique Charron (St Louis Hospital, Paris, France), Helmut Drexler (Hannover Medical school, Germany), Andre Terzic (Mayo Clinic, Rochester U.S.A) and Catherine Verfaillie (Leuven University, Belgium).
Dr Christian Homsy, CEO of Cardio3 BioSciences said: “The potential of cell therapies for the treatment of heart failure has long been recognised but there have been considerable hurdles to overcome in delivering on the promise. Today’s expert panel was able to provide a thorough review of the advancements in science that have brought about today’s second generation cell therapies and to put our product, C-Cure, into context. We believe C-Cure has tremendous potential to realise the promise of regenerative therapies in heart failure and look forward to the results of our pivotal trial.”
C-Cure draws on an unrivalled understanding of the fundamental science of heart cell development at the Mayo Clinic and within the Cardio3 BioSciences scientific in-house team. The product involves taking a patient’s own bone marrow cells and through a proprietary culturing technology, gives rise to ‘cardiopoietic’ cells that can regenerate damaged heart muscle. Unlike previous cell therapies for this indication, C-Cure is designed to produce new autologous heart muscle cells which behave identically to those lost in infarction without carrying the risk of rejection.
About Cardio3 BioSciences
Cardio3 BioSciences is a leading Belgian biotechnology company specialising in stem cell-based therapies for the treatment of cardiovascular disease. The Company’s lead product, C-Cure, is a highly innovative approach to the treatment of heart failure, one of the world’s most pressing unmet medical needs. Based on a strategy developed by Cardio3 BioSciences’ founders and leveraging technology from Mayo Clinic, C-Cure allows the differentiation of a patient’s own cells into ‘cardiopoeitic’ cells which grow into new heart cells and repair heart muscle.
The Cardio3 BioSciences team has extensive experience in developing and commercialising new pharmaceutical products and medical technologies and the Company’s strategy is to drive the clinical development of C-Cure and to market the product itself in major territories. Cardio3 BioSciences was founded in July 2007 and is based in Mont-Saint-Guibert in the Walloon region of Belgium.
SOURCE Cardio3 BioSciences
CONTACT: For more information contact: Cardio3 BioSciences, Mayra Beydoun,
Brand & Communication Manager, Tel : +32-10-39-41-00, mbeydoun@c3bs.com;
Citigate Dewe Rogerson, Chris Gardner/Nina Enegren, Tel :
+44(0)207-638-9571, chris.gardner@citigatedr.co.uk,
nina.enegren@citigatedr.co.uk
